Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastrointest Oncol. May 15, 2014; 6(5): 139-144
Published online May 15, 2014. doi: 10.4251/wjgo.v6.i5.139
Published online May 15, 2014. doi: 10.4251/wjgo.v6.i5.139
Ref. | Patients (n) | Adeno-carcinoma (%) | Treatment intention of studied group | Median (or mean) SUVmax | SUVmax significant on univariate analysis | SUVmax significant on multivariate analysis | Other significant associations on multivariate analysis |
Fukunaga et al[4], 1998 | 48 | Not stated | Curative | 7 | Yes | Not assessed | Not assessed |
Choi et al[5], 2004 | 69 | 0% | Curative | 6.3/13.7 (thresholds) | Yes | No | UICC stage |
Hong et al[6], 2005 | 47 | 87% | Curative | Not stated | No | No | Number of abnormalities on PET-CT |
Stahl et al[7], 2005 | 40 | 100% | Curative | 10.5 | No | Not assessed | |
van Westreenen et al[8], 2005 | 40 | 70% | Curative and palliative | 6.7 | Yes | No | Treatment |
Cerfolio et al[9], 2006 | 89 | 53% | Curative | 6.6 | Yes | Yes | UICC stage |
Choi et al[10], 2006 | 51 | 0% | Curative | Not stated | Yes | No | UICC stage, N1 status (on PET-CT), immunohistochemical markers |
Westerterp et al[11], 2008 | 26 | 100% | Curative | 0.26 | Yes | Not assessed | |
Omloo et al[12], 2008 | 125 | 85% | Curative | 0.27 | Yes | No | UICC stage |
Cheze-Le Rest et al[13], 2008 | 47 | 77% | Curative | 9 | Yes | Yes | Treatment, number of abnormalities on PET-CT |
Chatterton et al[14], 2008 | 129 | 19% | Curative and palliative | 8.2 | No | Not assessed | Not assessed |
Makino et al[15], 2008 | 38 | 100% | Curative | 11.1 | Yes | No | N1 status (on PET-CT) |
Javeri et al[16], 2009 | 161 | 100% | Curative | 10.1 | No | No | |
Kato et al[17], 2009 | 184 | 0% | Curative | 4.5 | Yes | Yes | N1 status |
Rizk et al[18], 2009 | 189 | 100% | Curative | 4.5 (preset threshold) | Yes | Not assessed | Not assessed |
Sepesi et al[19], 2009 | 72 | 83% | Curative | 6.2 | Yes | Yes | |
Shenfine et al[20], 2009 | 45 | 100% | Curative | 5.7 | Yes | No | UICC stage |
Hyun et al[21], 2010 | 151 | 3% | Curative and palliative | 17.2 | Yes | No | UICC stage, metabolic tumor volume |
Brown et al[22], 2012 | 103 | 80% | Curative | 6.4 (early)/8.8 (later scans) | Yes | No | N1 status, age |
Gillies et al[23], 2012 | 121 | 100% | Curative | 8.5 | Yes | No | N1 status (on PET-CT) |
Chan et al[24], 2013 | 185 | 75% | Curative and palliative | 8.9 | Yes | No | N1 status, tumor volume on EUS |
- Citation: Al-Taan OS, Eltweri A, Sharpe D, Rodgers PM, Ubhi SS, Bowrey DJ. Prognostic value of baseline FDG uptake on PET-CT in esophageal carcinoma. World J Gastrointest Oncol 2014; 6(5): 139-144
- URL: https://www.wjgnet.com/1948-5204/full/v6/i5/139.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v6.i5.139